Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control <i>Mycoplasma hyopneumoniae</i> in Swine Production
<i>Mycoplasma hyopneumoniae</i> is a difficult-to-control bacterium since commercial vaccines do not prevent colonization and excretion. The present study aimed to evaluate the performance of an orally administered vaccine composed of antigens extracted from <i>Mycoplasma hyopneumo...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/7/6591 |
| _version_ | 1797607719787560960 |
|---|---|
| author | Gabriel Y. Storino Fernando A. M. Petri Marina L. Mechler-Dreibi Gabriel A. Aguiar Leonardo T. Toledo Laíza P. Arruda Clarisse S. Malcher Tereza S. Martins Hélio J. Montassier Osvaldo A. Sant’Anna Márcia C. A. Fantini Luís Guilherme de Oliveira |
| author_facet | Gabriel Y. Storino Fernando A. M. Petri Marina L. Mechler-Dreibi Gabriel A. Aguiar Leonardo T. Toledo Laíza P. Arruda Clarisse S. Malcher Tereza S. Martins Hélio J. Montassier Osvaldo A. Sant’Anna Márcia C. A. Fantini Luís Guilherme de Oliveira |
| author_sort | Gabriel Y. Storino |
| collection | DOAJ |
| description | <i>Mycoplasma hyopneumoniae</i> is a difficult-to-control bacterium since commercial vaccines do not prevent colonization and excretion. The present study aimed to evaluate the performance of an orally administered vaccine composed of antigens extracted from <i>Mycoplasma hyopneumoniae</i> and incorporated into mesoporous silica (SBA-15), which has an adjuvant-carrier function, aiming to potentiate the action of the commercial intramuscular vaccine. A total of 60 piglets were divided into four groups (n = 15) submitted to different vaccination protocols as follows, Group 1: oral SBA15 + commercial vaccine at 24 days after weaning, G2: oral vaccine on the third day of life + vaccine commercial vaccine at 24 days, G3: commercial vaccine at 24 days, and G4: commercial vaccine + oral vaccine at 24 days. On the first day, the piglets were weighed and, from the third day onwards, submitted to blood collections for the detection and quantification of anti-<i>Mycoplasma hyopneumoniae</i> IgG. Nasal swabs were collected to monitor IgA by ELISA, and oropharyngeal swabs were used to assess the bacterial load by qPCR. Biological samples were collected periodically from the third day of life until the 73rd day. At 41 days of life, 15 individuals of the same age, experimentally challenged with an inoculum containing <i>M. hyopneumoniae</i>, were co-housed with the animals from groups (1 to 4) in a single pen to increase the infection pressure during the nursery period. At 73 days, all piglets were euthanized, and lungs were evaluated by collecting samples for estimation of bacterial load by qPCR. Quantitative data obtained from physical parameters and laboratory investigation were analyzed by performing parametric or non-parametric statistical tests. Results indicate that animals from G2 showed smaller affected lung areas compared to G3. Animals from G2 and G4 had a low prevalence of animals shedding <i>M. hyopneumoniae</i> at 61 days of age. Additionally, no correlation was observed between lung lesions and <i>M. hyopneumoniae</i> load in lung and BALF samples in animals that received the oral vaccine, while a strong correlation was observed in other groups. In the present study, evidence points to the effectiveness of the oral vaccine developed for controlling <i>M. hyopneumoniae</i> in pig production under field conditions. |
| first_indexed | 2024-03-11T05:34:43Z |
| format | Article |
| id | doaj.art-4482cb296c4849cc8cb37dbb8d22a645 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T05:34:43Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-4482cb296c4849cc8cb37dbb8d22a6452023-11-17T16:53:18ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-04-01247659110.3390/ijms24076591Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control <i>Mycoplasma hyopneumoniae</i> in Swine ProductionGabriel Y. Storino0Fernando A. M. Petri1Marina L. Mechler-Dreibi2Gabriel A. Aguiar3Leonardo T. Toledo4Laíza P. Arruda5Clarisse S. Malcher6Tereza S. Martins7Hélio J. Montassier8Osvaldo A. Sant’Anna9Márcia C. A. Fantini10Luís Guilherme de Oliveira11School of Agricultural and Veterinarian Sciences, São Paulo State University (Unesp), Jaboticabal 14884-900, SP, BrazilSchool of Agricultural and Veterinarian Sciences, São Paulo State University (Unesp), Jaboticabal 14884-900, SP, BrazilSchool of Agricultural and Veterinarian Sciences, São Paulo State University (Unesp), Jaboticabal 14884-900, SP, BrazilSchool of Agricultural and Veterinarian Sciences, São Paulo State University (Unesp), Jaboticabal 14884-900, SP, BrazilLaboratório de Virologia Animal (LVA), Departamento de Veterinária, Universidade Federal de Viçosa, Avenida Peter Henry Rolfs s/n, Campus Universitário, Viçosa 36570-900, MG, BrazilSchool of Agricultural and Veterinarian Sciences, São Paulo State University (Unesp), Jaboticabal 14884-900, SP, BrazilSchool of Agricultural and Veterinarian Sciences, São Paulo State University (Unesp), Jaboticabal 14884-900, SP, BrazilDepartment of Chemistry, Federal University of São Paulo (UNIFESP), Diadema 09913-030, SP, BrazilSchool of Agricultural and Veterinarian Sciences, São Paulo State University (Unesp), Jaboticabal 14884-900, SP, BrazilButantan Institute, São Paulo 05508-040, SP, BrazilPhysics Institute, University of São Paulo (USP), São Paulo 05508-090, SP, BrazilSchool of Agricultural and Veterinarian Sciences, São Paulo State University (Unesp), Jaboticabal 14884-900, SP, Brazil<i>Mycoplasma hyopneumoniae</i> is a difficult-to-control bacterium since commercial vaccines do not prevent colonization and excretion. The present study aimed to evaluate the performance of an orally administered vaccine composed of antigens extracted from <i>Mycoplasma hyopneumoniae</i> and incorporated into mesoporous silica (SBA-15), which has an adjuvant-carrier function, aiming to potentiate the action of the commercial intramuscular vaccine. A total of 60 piglets were divided into four groups (n = 15) submitted to different vaccination protocols as follows, Group 1: oral SBA15 + commercial vaccine at 24 days after weaning, G2: oral vaccine on the third day of life + vaccine commercial vaccine at 24 days, G3: commercial vaccine at 24 days, and G4: commercial vaccine + oral vaccine at 24 days. On the first day, the piglets were weighed and, from the third day onwards, submitted to blood collections for the detection and quantification of anti-<i>Mycoplasma hyopneumoniae</i> IgG. Nasal swabs were collected to monitor IgA by ELISA, and oropharyngeal swabs were used to assess the bacterial load by qPCR. Biological samples were collected periodically from the third day of life until the 73rd day. At 41 days of life, 15 individuals of the same age, experimentally challenged with an inoculum containing <i>M. hyopneumoniae</i>, were co-housed with the animals from groups (1 to 4) in a single pen to increase the infection pressure during the nursery period. At 73 days, all piglets were euthanized, and lungs were evaluated by collecting samples for estimation of bacterial load by qPCR. Quantitative data obtained from physical parameters and laboratory investigation were analyzed by performing parametric or non-parametric statistical tests. Results indicate that animals from G2 showed smaller affected lung areas compared to G3. Animals from G2 and G4 had a low prevalence of animals shedding <i>M. hyopneumoniae</i> at 61 days of age. Additionally, no correlation was observed between lung lesions and <i>M. hyopneumoniae</i> load in lung and BALF samples in animals that received the oral vaccine, while a strong correlation was observed in other groups. In the present study, evidence points to the effectiveness of the oral vaccine developed for controlling <i>M. hyopneumoniae</i> in pig production under field conditions.https://www.mdpi.com/1422-0067/24/7/6591animal healthimmunologyinfectious diseasesrespiratory diseasesvaccinology |
| spellingShingle | Gabriel Y. Storino Fernando A. M. Petri Marina L. Mechler-Dreibi Gabriel A. Aguiar Leonardo T. Toledo Laíza P. Arruda Clarisse S. Malcher Tereza S. Martins Hélio J. Montassier Osvaldo A. Sant’Anna Márcia C. A. Fantini Luís Guilherme de Oliveira Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control <i>Mycoplasma hyopneumoniae</i> in Swine Production International Journal of Molecular Sciences animal health immunology infectious diseases respiratory diseases vaccinology |
| title | Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control <i>Mycoplasma hyopneumoniae</i> in Swine Production |
| title_full | Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control <i>Mycoplasma hyopneumoniae</i> in Swine Production |
| title_fullStr | Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control <i>Mycoplasma hyopneumoniae</i> in Swine Production |
| title_full_unstemmed | Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control <i>Mycoplasma hyopneumoniae</i> in Swine Production |
| title_short | Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control <i>Mycoplasma hyopneumoniae</i> in Swine Production |
| title_sort | use of nanostructured silica sba 15 as an oral vaccine adjuvant to control i mycoplasma hyopneumoniae i in swine production |
| topic | animal health immunology infectious diseases respiratory diseases vaccinology |
| url | https://www.mdpi.com/1422-0067/24/7/6591 |
| work_keys_str_mv | AT gabrielystorino useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT fernandoampetri useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT marinalmechlerdreibi useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT gabrielaaguiar useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT leonardottoledo useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT laizaparruda useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT clarissesmalcher useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT terezasmartins useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT heliojmontassier useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT osvaldoasantanna useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT marciacafantini useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction AT luisguilhermedeoliveira useofnanostructuredsilicasba15asanoralvaccineadjuvanttocontrolimycoplasmahyopneumoniaeiinswineproduction |